Valuation: Compass Therapeutics, Inc.

Market Cap 169M 151M 141M 128M 241M 16.14B 243M 1.69B 663M 8.33B 634M 620M 26.8B P/E 2026 *
-1.89x
P/E 2027 * -1.68x
Enterprise Value 18.83M 16.86M 15.72M 14.25M 26.89M 1.8B 27.05M 189M 73.93M 929M 70.74M 69.18M 2.99B EV / Sales 2026 *
-
EV / Sales 2027 * 5.5x
Free-Float
87.53%
Yield 2026 *
-
Yield 2027 * -
1 day-5.59%
1 week-2.40%
Current month-9.86%
1 month-53.12%
3 months-59.76%
6 months-81.87%
Current year-82.54%
1 week 0.92
Extreme 0.9202
1.06
1 month 0.83
Extreme 0.8294
2.04
Current year 0.83
Extreme 0.8294
6.88
1 year 0.83
Extreme 0.8294
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Buy

Controller/Auditor

20,000 0.0111%
24/9/26 Buy

Controller/Auditor

2,500 0.0014%
29/4/26 Buy

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-5.59%-2.40%-77.89%-49.87% 169M
+0.03%-5.67%+50.74%+76.76% 70.65B
+0.66%-9.75%+6.97%+52.62% 51.22B
+0.31%-0.14%+8.84%+32.99% 48.04B
+0.90%-1.46%+32.32%+32.69% 43.16B
+2.21%-6.61%+302.05%+701.45% 41.57B
-1.15%-3.11%+9.47%+98.83% 39.84B
+0.45%-1.20%+9.11%+43.54% 30.87B
-3.13%-11.74%+41.71%+4.07% 27.53B
-1.16%-1.84%-6.09%-11.99% 24.08B
Average -0.63%-3.32%+37.72%+98.11% 37.71B
Weighted average by Cap. +0.11%-3.47%+52.94%+120.31%

Financials

2026 *2027 *
Net sales - 6.51M 5.83M 5.43M 4.93M 9.3M 622M 9.36M 65.31M 25.57M 321M 24.46M 23.92M 1.03B
Net income -93.27M -83.49M -77.83M -70.6M -133M -8.92B -134M -935M -366M -4.6B -350M -343M -14.81B -112M -100M -93.23M -84.56M -159M -10.68B -160M -1.12B -439M -5.51B -420M -410M -17.73B
Net Debt -150M -134M -125M -114M -214M -14.34B -215M -1.5B -589M -7.4B -563M -551M -23.81B -133M -119M -111M -101M -190M -12.71B -191M -1.33B -522M -6.56B -500M -489M -21.11B
Projected Income Statement - Annual - Compass Therapeutics, Inc.
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
12/10/26 USD 0.9375 -5.59% 4,436,731
09/10/26 USD 0.9930 +0.98% 3,670,889
08/10/26 USD 0.9834 -3.59% 7,042,690
07/10/26 USD 1.020 +2.19% 2,792,590
06/10/26 USD 0.9981 +3.90% 7,286,326
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Compass Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
0.9375USD
Average target price
5.455USD
Spread / Average Target
+481.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Compass Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CMPX Stock